- Home
- ACAD
as of 02-18-2026 3:47pm EST
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
| Founded: | 1993 | Country: | US |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.9B | IPO Year: | 2000 |
| Target Price: | $29.95 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.69 | EPS Growth: | 467.57 |
| 52 Week Low/High: | $14.08 - $28.35 | Next Earning Date: | 04-12-2026 |
| Revenue: | $726,437,000 | Revenue Growth: | 40.45% |
| Revenue Growth (this year): | 15.06% | Revenue Growth (next year): | 11.34% |
| P/E Ratio: | 33.59 | Index: | N/A |
| Free Cash Flow: | 157.2M | FCF Growth: | -2.39% |
AI-Powered ACAD Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ACADIA Pharmaceuticals Inc. (ACAD)
EVP, CHIEF LEGAL OFFICER, SEC
Avg Cost/Share
$23.38
Shares
6,950
Total Value
$162,491.00
Owned After
7,609
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Rhodes Jennifer J | ACAD | EVP, CHIEF LEGAL OFFICER, SEC | Feb 9, 2026 | Sell | $23.38 | 6,950 | $162,491.00 | 7,609 |
Compare ACAD vs Leading Stocks
See how ACAD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ACAD ACADIA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.